Search results
Showing 16 to 23 of 23 results for aflibercept
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943
Topic prioritisation
This guideline covers managing and monitoring diabetic retinopathy in people under the care of hospital eye services. This includes non-proliferative and proliferative diabetic retinopathy, and diabetic macular oedema.
associated with inconvenience, risk of adverse events and – especially when aflibercept or ranibizumab is used – substantial costs....
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Past technology appraisal appeals and decisions
Visual impairment due to myopic choroidal neovascularisation: aflibercept (ESNM76)
This evidence summary has been replaced by NICE technology appraisal guidance 486.
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).